CN114793435B - 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物 - Google Patents

用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物 Download PDF

Info

Publication number
CN114793435B
CN114793435B CN202080078998.0A CN202080078998A CN114793435B CN 114793435 B CN114793435 B CN 114793435B CN 202080078998 A CN202080078998 A CN 202080078998A CN 114793435 B CN114793435 B CN 114793435B
Authority
CN
China
Prior art keywords
compound
heterocycloalkyl
nrr
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080078998.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114793435A (zh
Inventor
R·克斯特勒
M·托尔曼
J·塔塞尔
N·叶海亚
A·特雷姆尔
M·阿尔姆施泰特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Origenis GmbH
Original Assignee
Origenis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis GmbH filed Critical Origenis GmbH
Priority to CN202411291626.2A priority Critical patent/CN119775277A/zh
Publication of CN114793435A publication Critical patent/CN114793435A/zh
Application granted granted Critical
Publication of CN114793435B publication Critical patent/CN114793435B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
CN202080078998.0A 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物 Active CN114793435B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411291626.2A CN119775277A (zh) 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962899908P 2019-09-13 2019-09-13
US62/899,908 2019-09-13
PCT/IB2020/000730 WO2021048620A1 (en) 2019-09-13 2020-09-11 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411291626.2A Division CN119775277A (zh) 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物

Publications (2)

Publication Number Publication Date
CN114793435A CN114793435A (zh) 2022-07-26
CN114793435B true CN114793435B (zh) 2024-10-01

Family

ID=72801756

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080078998.0A Active CN114793435B (zh) 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物
CN202411291626.2A Pending CN119775277A (zh) 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411291626.2A Pending CN119775277A (zh) 2019-09-13 2020-09-11 用于治疗例如自身免疫性疾病的作为lrrk2、nuak1和/或tyk2激酶调节剂的化合物

Country Status (17)

Country Link
US (1) US20220380374A1 (https=)
EP (2) EP4327884A3 (https=)
JP (2) JP7796007B2 (https=)
KR (1) KR20220062038A (https=)
CN (2) CN114793435B (https=)
AU (1) AU2020344216A1 (https=)
CA (1) CA3154123A1 (https=)
DK (1) DK4028017T3 (https=)
ES (1) ES2969088T3 (https=)
FI (1) FI4028017T3 (https=)
HU (1) HUE065093T2 (https=)
IL (1) IL291335A (https=)
PL (1) PL4028017T3 (https=)
PT (1) PT4028017T (https=)
RS (1) RS65045B1 (https=)
SI (1) SI4028017T1 (https=)
WO (1) WO2021048620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7796007B2 (ja) * 2019-09-13 2026-01-08 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2022548581A (ja) * 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143143A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350086B1 (en) 2008-09-23 2021-04-21 The Johns Hopkins University Fused diimidazodiazepine compounds and methods of use and manufacture thereof
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
JP7796007B2 (ja) * 2019-09-13 2026-01-08 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143143A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors

Also Published As

Publication number Publication date
PT4028017T (pt) 2024-01-16
PL4028017T3 (pl) 2024-03-18
CA3154123A1 (en) 2021-03-18
IL291335A (en) 2022-05-01
DK4028017T3 (da) 2024-01-15
SI4028017T1 (sl) 2024-04-30
FI4028017T3 (fi) 2024-01-11
EP4028017B1 (en) 2023-12-06
EP4327884A3 (en) 2024-05-01
HUE065093T2 (hu) 2024-05-28
WO2021048620A1 (en) 2021-03-18
CN114793435A (zh) 2022-07-26
RS65045B1 (sr) 2024-02-29
AU2020344216A1 (en) 2022-03-31
ES2969088T3 (es) 2024-05-16
JP2025081660A (ja) 2025-05-27
JP2022548246A (ja) 2022-11-17
EP4028017A1 (en) 2022-07-20
JP7796007B2 (ja) 2026-01-08
US20220380374A1 (en) 2022-12-01
CN119775277A (zh) 2025-04-08
KR20220062038A (ko) 2022-05-13
EP4327884A2 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
US12384788B2 (en) 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease
JP2025081660A (ja) 例えば自己免疫疾患の処置のための、ＬＲＲＫ２、ＮＵＡＫ１および／またはＴＹＫ２キナーゼモジュレータとしての１，４－ジヒドロベンゾ［ｄ］ピラゾロ［３，４－ｆ］［１，３］ジアゼピン誘導体および関連する化合物
CA3208988A1 (en) 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3
US12110299B2 (en) Thiazole derivatives and pharmaceutically acceptable salts thereof
WO2022011338A2 (en) Kinase modulators and methods of use thereof
US20240174647A1 (en) Kinase modulators and methods of use thereof
WO2023192506A1 (en) Malt1 modulators and uses thereof
EP4243816A1 (en) Kinase modulators and methods of use thereof
US20230373985A1 (en) Kinase modulators and methods of use thereof
US20240208972A1 (en) Lrrk2 inhibitors and uses thereof
EP4584273A1 (en) Lrrk2 inhibitors and uses thereof
US20240228493A1 (en) Lrrk2 inhibitors and uses thereof
WO2025137541A1 (en) Kinase modulators and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant